Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Latest Information Update: 15 Mar 2025
At a glance
- Drugs Antithymocyte globulin (Primary) ; Blinatumomab (Primary) ; Cyclophosphamide (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Rituximab (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Thiotepa (Primary)
- Indications Haematological malignancies; Lymphoid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Non-Hodgkin's lymphoma; Sarcoma
- Focus Therapeutic Use
- 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
- 05 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.